For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D).
